Human-Relevant Discovery: iPSC Models and the Future of Rare Disease R&D
February 25, 2026
A Q&A with iXCells Biotechnologies CEO, Steve Smith
8 min read
False
Advertisement
Drug Discovery
Syngene and Johns Hopkins Partner to Advance Early-Stage Drug Discovery
February 25, 2026
Collaboration anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research
1 min read
Building Better Oral Suspensions for Pediatric & Real-World Use
February 18, 2026
Greg Thomas, Kiel Laboratories’ Vice President of R&D, discusses oral suspensions, excipients, and patient-centered formulation
4 min read
Oral BTK Inhibitor Shows Disability Benefit in Progressive Multiple Sclerosis Trial
February 17, 2026
Phase 3 results show fenebrutinib matched OCREVUS on disability progression in PPMS
2 min read
The Role of AI in Rare Disease Drug Discovery
By Dan Williams
February 6, 2026
AI, data-sharing, and gene technologies are peering into the future of rare disease drug development, and overcoming economic, regulatory, and diagnostic challenges for transformative therapies.
9 min read
Five Ways AI Will Reshape Life Sciences in 2026
By Chris Moore
February 5, 2026
Why people, process, and purpose matter most
5 min read
How AI and CDMO/CRO Integration is Key to the Future of Drug Development
By Jennifer Cannon
February 3, 2026
The next era of drug development will be connected, data-driven and centered on patient impact
4 min read
Schistosomiasis: The Need for a Tailored-Made Treatment for Preschoolers
January 15, 2026
About the Pediatric Praziquantel Consortium, and why a child-friendly treatment for preschool-aged children with schistosomiasis was needed
13 min read
A Turning Point in MASH
By HH Kim
January 8, 2026
A billion-dollar acquisition, breakthrough clinical data, and a shifting scientific paradigm are pushing MASH out of the shadows and into a new era of metabolic medicine.
3 min read
The Post-Pandemic Evolution of Antiviral Research
December 22, 2025
The pandemic catalyzed a transformation in antiviral R&D. From better data to open collaboration, Tetiana Matviyuk of Enamine describes how the landscape has evolved.
3 min read
